Dyadic International Inc., operating as Dyadic Applied BioSolutions, announced significant scientific research achievements across its life sciences and food and nutrition portfolios. The company reported that its recombinant DNase I has met required activity and purity benchmarks, validating its suitability for molecular biology, diagnostics, and biopharma applications; this product is now being produced at research grade for direct sales and OEM supply. In collaboration with Proliant Health & Biologicals, Dyadic reached a major productivity milestone in the development of recombinant human albumin, with commercialization and product sampling underway and a full launch targeted for late 2025 to early 2026. In the food and nutrition sector, Dyadic signed a term sheet to develop non-animal human alpha-lactalbumin for infant nutrition and is currently sampling non-animal bovine alpha-lactalbumin for broader markets. Additionally, through its partnership with Inzymes ApS, Dyadic achieved productivity improvements in non-animal dairy enzymes, with the first enzyme's commercial launch expected by late 2025. These results have been achieved and are supporting ongoing commercialization and partner discussions.